Get started

PHARMA

Novo Nordisk (Revised) | NVO | Long at $47.78**This is a revised analysis from February 5, 2025: I am still in that position, but added significantly more below $50** Novo Nordisk NYSE:NVO is now trading at valuations before its release of Wegovy and Ozempic... From a technical analysis perspective, it's within my "major crash" simple moving average zone (gray lines). When a company's stock price enters this region (especially large and healthy companies) I always grab shares - either for a temporary future bounce or a long-term hold. While currently trading near $47 a share, I think worst case scenario here in 2025 is near $38-$39. Tariffs may cause a recession in the second half of 2025, so no company would be immune. As mentioned above, I am still a holder at $86.74. However, I went in much heavier within my "major crash" simple moving average band and have a final entry planned near $38-$38 (if it drops there). My current cost average is near $55.00. Why do I still have faith in NYSE:NVO ? Because no one else does right now, yet it generated $42 billion in revenue, $14 billion in profits, and has significant cash flow YoY. The company has a massive pipeline, despite Wegovy and Ozempic competition, and I think the market is undervaluing its position in the pharmaceutical industry. Revised Targets in 2028: $60.00 (+25.6%) $70.00 (+46.5%) $80.00 (+67.4%)
NYSE:NVOLong
by WorthlessViews
Is Novo Nordisk a buy? Novo Nordisk $NYSE: NVO plummets 22% on July 29, wiping out $57.5B in market value! Here's what's happening and how I see it. Here’s the breakdown on why the stock hit its lowest since Nov 2022: Slashed 2025 Guidance: Sales growth cut to 8–14% from 13–21%, operating profit to 10–16% from 16–24%. Weak U.S. demand for Wegovy & Ozempic, plus competition from cheaper compounded GLP-1 drugs (i.e. grey market), cited as key issues. CEO Shake-Up: Lars Fruergaard Jørgensen out, Maziar Doustdar in as CEO effective Aug 7. Investors worry Doustdar’s limited U.S. experience could hurt Novo’s edge in its biggest market (57% of sales). Competition: Eli Lilly’s Zepbound (20.2% weight loss vs. Wegovy’s 13.7%) & Mounjaro are stealing market share. Compounded GLP-1s from Hims & Hers add pricing pressure. Here's what I see: There's a strong bearish sentiment, but the stock is very underpriced. Considering the current stock price, EPS is at an all-time high. This means investors get more earnings for their stock. P/B, P/E, and P/S ratios are at the lowest level since 2017! This is despite revenue growth of 25%+ for 3 consecutive years. Operating margins are still quite healthy. The company still has a very significant share (over 50%) of the GLP1 drugs worldwide. The valuation of this company is now at the best level of the last 7-8 years. There might be more volatility ahead, but I see the recent price drop as an opportunity to buy a pharma giant at a big discount, giving investors a margin of safety. Quick note: I'm just sharing my journey - not financial advice! 😊
NYSE:NVOLong
by HenriqueCentieiro
2
Sarepta's Plunge: A Confluence of Challenges?Sarepta Therapeutics (SRPT) faces significant market headwinds. The company's stock has seen a notable decline. This stems from multiple, interconnected factors. Its flagship gene therapy, ELEVIDYS, is central to these challenges. Recent patient deaths linked to similar gene technology raised safety concerns. The FDA requested a voluntary pause in Elevidys shipments. This followed a "black box warning" for liver injury. The confirmatory EMBARK trial for Elevidys also missed its primary endpoint. These clinical and regulatory setbacks significantly impacted investor confidence. Beyond specific drug issues, broader industry dynamics affect Sarepta. Macroeconomic pressures, like rising interest rates, reduce biotech valuations. Geopolitical tensions disrupt global supply chains. They also hinder international scientific collaboration. The intellectual property landscape is increasingly complex. Patent challenges and expirations threaten revenue streams. Cybersecurity risks also loom large for pharmaceutical companies. Data breaches could compromise sensitive R&D and patient information. The regulatory environment is evolving. The FDA demands more robust confirmatory data for gene therapies. This creates prolonged uncertainty for accelerated approvals. Government initiatives, like the Inflation Reduction Act, aim to control drug costs. These policies could reduce future revenue projections. Sarepta's reliance on AAV technology also presents inherent risks. Next-generation gene editing technologies could disrupt its current pipeline. All these factors combine to amplify each negative impact. Sarepta's recovery depends on strategic navigation. Securing full FDA approval for Elevidys is crucial. Expanding its label and maximizing commercial potential are key. Diversifying its pipeline beyond a single asset could de-risk the company. Disciplined cost management is essential in this challenging economic climate. Collaborations could provide financial support and expertise. Sarepta's journey offers insights into the broader gene therapy sector's maturity.
NASDAQ:SRPTShort
by UDIS_View
ABCL: When biotechnology not only curesABCL: When biotechnology not only cures, but also makes your wallet happy! Hello, fellow investors and those who just like to tickle your nerves on the stock exchange! Today we have on our agenda (and on the chart) - the stock AbCellera Biologics Inc. (ABCL), which seems to have decided to prove that even at the bottom there is life, and then even throw a party with a breakthrough! As you can see, our hero ABCL has been playing ‘hide and seek with the trend line’ for a long time, showing an enviable resilience in the fall, just like your sofa after a day at work. However, if you look closely, the ‘ma/ema below price’ signalled that buyers, like secret agents, had already taken control of the situation, preparing for the decisive throw. And here it is, it's happening! The recent ‘breakout + retest’ is not just a technical term, but a real escape from the ‘bearish’ prison with a subsequent test of strength. Not only did price break through resistance, but it came back to see if it was indeed broken. It's like going out of the house, forgetting your keys, coming back in, getting them, and then going out again - only in the stock market it's a sign of strength and determination! Now that the dust has settled and the ‘1d’ trendline is behind us, our sights are set on the upside. Targets? Of course! ‘tp1-4.81’ and ‘tp2-6.00’ are not just numbers, they are potential points where we can pat ourselves on the shoulder and say, ‘I told you so!’. А ‘2,618 (6,61)’ - is for the very brave and patient who are willing to wait for the true bull dance. All in all, ABCL seems to have turned a page in its history, swapping sad ballads for upbeat dance hits. But remember, friends: the market is a capricious thing, and even the most beautiful charts can bring surprises. So, act wisely, don't forget about risks and, of course, enjoy the process! Have a good trading!
NASDAQ:ABCLLong
by TotoshkaTrades
SWING IDEA - NEULAND LABNeuland Lab , a niche API manufacturer with strong export presence and leadership in complex molecules, is offering a technically strong swing trade opportunity from key support levels. Reasons are listed below : 11,500 zone acting as a crucial support area Formation of a hammer candle on the weekly timeframe, signaling potential reversal Reversing from the 0.618 Fibonacci retracement zone – the golden pocket Taking support at the 50-week EMA , holding long-term trend structure Target - 14900 // 17600 Stoploss - weekly close below 10215 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:NEULANDLABLong
by Visionary_Growth_Insights
SWING IDEA - AJANTA PHARMAAjanta Pharma , a mid-cap pharma player with strong branded generics in ophthalmology, dermatology, and cardiology, is showing a compelling swing trade setup backed by a high-probability technical breakout. Reasons are listed below : Bullish engulfing candle on the weekly timeframe, indicating reversal strength 2,500 zone acting as a crucial support Holding above 0.382 Fibonacci retracement level , suggesting healthy correction Price trading above 50 & 200 EMA on the weekly chart – long-term strength intact Breakout from narrow consolidation near the 50-week EMA Target - 3080 // 3400 Stoploss - weekly close below 2415 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:AJANTPHARMLong
by Visionary_Growth_Insights
Teva: The flag’s ready — someone just needs to hit “launch”Teva Pharmaceutical (TEVA) is setting up for a potential continuation move after a clean impulse. On the daily chart, we have a textbook bull pennant — and not just any sloppy one. Price has broken above the 200-day moving average, and all key EMAs (50/100/200) now sit below price, confirming a solid bullish structure. Volume behavior fits the script: declining inside the pennant, signaling pressure is building. More importantly, the Volume Profile reveals a low-volume void above current levels — meaning there’s little resistance until we hit the $22+ zone. In other words, once this breaks, it could run fast. RSI is comfortably in bullish territory without being overheated, and the flagpole projection gives us clean upside targets: – Entry: breakout above pennant resistance – Target: $22.80 — full flagpole height – Support: $17.60 — confluence of 0.5 Fib + volume base TEVA isn’t asking for confirmation anymore — it’s showing it. All systems are technically armed. Now we just wait for the market to press the button.
NYSE:TEVALong
by TotoshkaTrades
Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take... It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me: • Lacks symmetry • Had chances to break down, but no real follow-through 🧭 Where are we headed? I think pressure remains, and we could dip toward the 50% retracement of the 2023 move — that’s around 646. 🔁 If we bounce from there, I’ll shift my bias to a recovery and resumption of the long-term uptrend. Disclaimer: The information posted on Trading View is for informative purposes and is not intended to constitute advice in any form, including but not limited to investment, accounting, tax, legal or regulatory advice. The information therefore has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. Opinions expressed are our current opinions as of the date appearing on Trading View only. All illustrations, forecasts or hypothetical data are for illustrative purposes only. The Society of Technical Analysts Ltd does not make representation that the information provided is appropriate for use in all jurisdictions or by all Investors or other potential Investors. Parties are therefore responsible for compliance with applicable local laws and regulations. The Society of Technical Analysts will not be held liable for any loss or damage resulting directly or indirectly from the use of any information on this site.
NYSE:LLY
by The_STA
Merck & Company Potential Post Tariff Resolution Bullish RallyWith potential developments towards the resolution of global tariffs and pharma being defensive in general, MRK price action seems to exhibit signs of a potential Bullish reversal breakout as the price action may form a prominent Higher High with multiple confluences through key Fibonacci and Support levels which presents us with a potential Non-Leverage hold opportunity. Entry: (Buy 1 CMP 76.2 & Buy 2 87.6) Stop Loss: 45 or 0 (depends on trading style as Non-Leverage Buy & Hold is recommended) Potential Range for Targets: 130 - 170
NYSE:MRKLong
by LevelsBySBT
ImmunityBio: Catalyst for a New Era?ImmunityBio, Inc. is rapidly emerging as a significant force in the biotechnology sector, propelled by the success and expanding potential of its lead immunotherapy asset, ANKTIVA® (nogapendekin alfa inbakicept-pmln). The company achieved a pivotal milestone with the FDA approval of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This approval addresses a critical need and leverages ANKTIVA's unique mechanism as a first-in-class IL-15 agonist, designed to activate key immune cells and induce durable responses. Building on this success, ImmunityBio is actively pursuing global market access, submitting applications to the EMA and MHRA for potential approval in Europe and the UK by 2026. Beyond regulatory progress, ImmunityBio proactively tackles challenges in patient care, notably addressing the U.S. shortage of TICE® BCG. Through an FDA-authorized Expanded Access Program, the company supplies recombinant BCG (rBCG), providing a vital alternative source and expanding treatment access, particularly in underserved areas. This initiative supports patients and establishes a new market channel for ImmunityBio's therapies. Commercially, ANKTIVA's U.S. launch gains momentum, facilitated by a permanent J-code that simplifies billing and broadens insurance coverage, reaching over 240 million lives. ImmunityBio's strategic vision extends to other major cancer types. The company is advancing ANKTIVA's potential in non-small cell lung cancer (NSCLC) through a confirmatory Phase 3 trial with BeiGene. This collaboration follows promising Phase 2 data demonstrating ANKTIVA's ability to rescue checkpoint inhibitor activity in patients who have progressed on prior therapies, showing prolonged overall survival. This highlights ANKTIVA's broader potential as a foundational cytokine therapy capable of addressing lymphopenia and restoring immune function across various tumors. ImmunityBio's recent financial performance reflects this clinical and commercial traction, marked by a significant revenue increase driven by ANKTIVA sales and positive investor sentiment.
NASDAQ:IBRXLong
by UDIS_View
A Long-term Bullish Trend ?With an upcoming Earnings report we can observe rather uncertain future behavior. But since the trend has been bearish for a longer period of time and the price is "nearly" at the same position which was achieved for the first time in early April in 2019, we can, mostly based only on the technical analysis and Earnings report, determine quite confidently that the price is ready to rise. Important data: EPS Estimate: -$3.12 Revenue Estimate: $106 million to $166.7 million Notable developments: Cost-cutting initiative = Targeting $1.1B in reductions by 2027 By the end of 2024 $9.5 billion allocated in investments
NASDAQ:MRNALong
by Tears_of_Yeltsin
2
Undervalued, Oversold, Overlooked: MRK Hits The Key Zone!Hi all, Merck & Co. (MRK) is a global pharmaceutical titan and is currently trading near its 52-week low of ~$79. Anchored by Keytruda’s 7% YoY revenue growth, a stable ~4% dividend yield, and an average fair value estimate of $156.59 (98% upside), MRK appears significantly undervalued. Analysts forecast a 12-month price target of $118.05, implying 49% upside, supported by a strong pipeline and solid financials. While tariff concerns and Keytruda’s 2028 patent expiration pose risks. Technically speaking, MRK has fallen 43% from its all-time high and has reached the strongest area on the chart—a key support zone offering a compelling opportunity to build mid- or long-term positions. This critical area is defined by multiple technical factors, creating a high-probability setup for a potential reversal: Role Reversal Support: A broad, well-established resistance zone, aged like fine wine, has now flipped to act as support. This classic role reversal provides significant confluence to the setup. Textbook Trendline: A perfectly respected trendline, straight out of technical analysis textbooks, has consistently held. The price has approached this trendline from higher highs, underscoring its strength as a key support level. 50% Retracement Level: A critical level often watched for potential reversals. Monthly EMA200 Confluence: The 200-period exponential moving average on the monthly chart adds further strength to this area, reinforcing its technical significance. Strategic Guidance: This setup requires strong conviction. If you’re not prepared to buy in the lower gray areas of this support zone (marked on the chart), do not initiate a position. In today’s market sentiment, your fundamental research must be robust, and technical analysis allows you to get that much confidence to make it happen! Ask yourself: If the price falls further into the gray zones, am I willing to buy more? If your answer is yes, the current price presents a strong entry point for mid- to long-term positions. If the answer is no—if you’re unsure about buying at lower levels or find yourself questioning what to do if prices drop further—refrain from starting a position. In volatile markets, clarity and discipline are essential. Only enter if your strategy is clear and your conviction matches the opportunity! Good luck, Vaido
NYSE:MRKLong
by VaidoVeek
Pfizer ($PFE): Undervalued Pharma Giant with Growth Potential?(1/9) Good afternoon, everyone! 😊 Pfizer ( NYSE:PFE ): Undervalued Pharma Giant with Growth Potential? With PFE at $25.90, is this the time to buy into this pharmaceutical powerhouse? Let’s dive in! 😎 (2/9) – PRICE PERFORMANCE • Current Price: $25.90 as of March 12, 2025 😏 • Recent Moves: Trading within a range of $24 to $28, currently near the middle 😬 • Sector Vibe: Pharma sector remains stable, with new drug approvals driving growth 📈 Short commentary: The stock seems to be consolidating. Is this a good entry point? 🤔 (3/9) – MARKET POSITION • Market Cap: Approximately $147.2 billion (assuming 5.67 billion shares outstanding) 💰 • Operations: Global pharmaceutical company with a diverse product portfolio 🛡️ • Trend: Strong Q4 2024 earnings and reaffirmed 2025 guidance 🚀 Short commentary: Pfizer’s fundamentals are solid, with consistent revenue and earnings projections. 😉 (4/9) – KEY DEVELOPMENTS • Reaffirmed 2025 revenue guidance of $61-64 billion and EPS of $2.80-3.00 📈 • Continued focus on new drug developments and expanding into emerging markets 🌐 • Achieved cost savings goals and ongoing optimization programs for improved margins 💡 Short commentary: The company is managing its costs effectively and looking to future growth. Let’s watch closely. 👀 (5/9) – RISKS IN FOCUS • Legal challenges related to past products ⚙️ • Competition from generic manufacturers and patent expirations 📉 • Economic conditions affecting healthcare spending ⚠️ Short commentary: These risks are known, but Pfizer’s diverse portfolio should help mitigate them. Stay vigilant! 🕵️ (6/9) – SWOT: STRENGTHS • Diverse product portfolio across multiple therapeutic areas 🏆 • Strong R&D capabilities and pipeline of new drugs 🌈 • Global presence and distribution network 🌟 Short commentary: Pfizer’s strengths position it well for long-term growth. Keep up the good work! 👍 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Dependence on key products, legal issues ⚠️ • Opportunities: New drug approvals, expanding into emerging markets 🌐 Short commentary: Opportunities abound, but weaknesses need to be monitored. Let’s hope they nail it! 📈 (8/9) – PFE at $25.90 – what’s your call? 🗳️ • Bullish: Price could rise to $30+ if it breaks above $28 🚀 • Neutral: Price remains between $24 and $28 😐 • Bearish: Price could drop to $22 if it breaks below $24 📉 Drop your pick below! 💬 (9/9) – FINAL TAKEAWAY Pfizer’s $25.90 stance shows a company with solid fundamentals and a fair valuation at a P/E of approximately 8.93. With a strong pipeline and cost management, it’s an attractive option for value investors. Keep an eye on resistance at $28 for potential upside movement. Snag low, hold long!
NYSE:PFELong
by DCAChampion
Finally a stock I like...this one is a real dealFinally, an investment idea! (after how much doom and gloom?) — Novo Nordisk. You will all be familiar with Ozempic, the Danish company’s flagship product and the reason so many celebrities, influencers, b listers and regular schmegular Americans are suddenly skinny. I ignored the stock for most of ‘23/24, because it was so expensive. I am still a value investor (for my sins) and I just didn’t see a lot of value there — it was priced in. Imagine my surprise as I was thinking about “megatrends” (vom) for the year ahead — AI, data, 'zempy. Novo stock has fallen 37.80% in the last six months. And you know what that means…that’s a real deal! Why is it a real deal? (Don’t you like booze stocks Eden?) Ozempic is not going away. At this point it is synonymous with weight loss as “Uber” is to ridesharing or Google is to search. Note this data per Barclays, from recently issued rx data in the US — Ozempic script issuance has grown +8.4%, while WeGovy slightly trails it at 7.4% — both owned by Novo. While Eli Lilly also makes a GLP, Novo is still the leader. Strong guidance from management on sales — +16% - 24% — roughly implies revenue of $48bn for ‘25 and $57bn for ‘26…that’s a compounder. America and much of the western world has an obesity problem. There is a clear incentive for governments to underwrite the drug because obesity has a clear social + fiscal cost on society — per UoA, the fiscal cost of obesity in NZ is at least $2bn¹. People have an incentive to use Ozempic, because they are vain. This is a nice hedge against the booze stocks I like so much. Benefit from both sides of the trade — buy booze at low teens multiples; buy Novo and benefit from lower drinking rates as there’s several studies that imply ‘Zempy reduces drinking. I don’t want Ozempic, because I like to live the good life. This does not mean the vast majority of people won’t use Ozempic. At the moment, one in eight Americans have used a GLP. That’s +334mn people. 40% of Americans are obsese. There’s a Lollapalooza effect happening here — a bunch of incentives — vain people, governments wanting less obese people, the various side health benefits of GLPs, etc. I like when a lot of incentives are aligned because you’re relying on psychology rather than projecting numbers on an excel spreadsheet. Novo has sold off recently due to a trial of its CagriSema drug missing expectations. Eyes on the prize, though — current GLPs, which still have plenty of market to saturate. Eli Lilly has traded up in recent times, while Novo has traded down. The two tend to trade in lockstep so the disconnect is an opportunity to buy the world’s leading GLP maker at a good price. Eli Lilly is the closest comp, but it trades at a 38x fwd multiple, while Novo trades at 20x — i.e. an almost 50% multiple discount (see chart). I like that too… Note analyst recs on chart also… This analysis is provided by Eden Bradfeld at BlackBull Research—sign up for their Substack to receive the latest market insights straight to your inbox.
NYSE:NVO
by BlackBull_Markets
1
Feroz Technical Analysis: Potential Buy OpportunityFeroz currently displays a bullish trend supported by key indicators. Price has rebounded from a trendline and is trading above the 89-day EMA, a historically significant support level respected by the price action. A recent support zone bounce and alignment with the Fibonacci Golden Ratio further strengthen the bullish outlook. Buy levels are 330 (CMP) and 310, with a stop-loss set on a closing price below 275. Happy trading!
PSX:FEROZLong
by TradeWithParas
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem with a massive market It recently launched a public offering to raise capital to fund general operations and in doing so diluted the share holders. The good news is it is unlikely to do another in the near term. An entry would be at the current price with a stop loss above the highest volume bar on the profile. The first target is the POC of the volume profile about a 15% price drop . The second target is the pivot low on August 1st for another 15% drop. Taking of 1/2 at each target yields an expected 23% return over a period of about 5 trading days since drops are faster than rises. The call options of mid September have low volumes so I will not consider them.
NASDAQ:LXRXShort
by AwesomeAvani